effect of operator expertise on the probability to detect csPCa in FB group, after accounting for all confounders.
INTRODUCTION AND OBJECTIVES:
The fusion of multiparametric (Mp) magnetic resonance imaging (MRI) with real time 3D ultrasound during prostate biopsy is gaining popularity. The aim of this study was to evaluate the diagnostic performance of Mp-MRI using a per-core analysis of patients who underwent prostate "fusion" biopsy.
METHODS: Baseline, clinical and pathological data of 498 consecutive patients who underwent Mp-MRI/ultrasound "fusion" biopsy of prostate were prospectively collected in three centres between October 2013 and October 2016. The UroStationÔ (Koelis, France) and ultrasound system with an end-fire 3D TRUS transducer were used for the imaging fusion process. Diagnostic accuracy of Mp-MRI was evaluated in the whole cohort and in those patients with Gleason score >6, separately. Sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and accuracy (Ac) of Mp-MRI were assessed on the base of a per core analysis of histologic findings.
RESULTS: Demographic data are reported into In a per core analysis, the PPV of PI-RADS scores 3,4 and 5 were 8.5%, 37.8% and 73.2%, respectively, while the PPV of PI-RADS scores for Gleason score PCa>6 were 5.1%, 21.2% and 62.2%, respectively. (Table 2) .
CONCLUSIONS: This study confirmed high PCa detection rates with Mp-MRI-ultrasound fusion biopsy. A meticulous analysis of 9360 biopsy cores taken showed a poor sensitivity and PPV of Mp-MRI, especially for Gleason score >6 PCa. Despite the poor discrimination of PI-RADS scores of 3 and 4, PIRADS scores 5 correctly identified PCa lesions with Gleason scores >6.
Source of Funding: none

MP03-07 COMBINED CLINICAL PARAMETERS AND MULTIPARAMETRIC MRI FOR PREDICTION OF SIDE-SPECIFIC EXTRAPROSTATIC DISEASE -A RISK-MODEL FOR PATIENT-TAILORED RISK STRATIFICATION BEFORE RADICAL PROSTATECTOMY
INTRODUCTION AND OBJECTIVES: Multiparametric MRI (mpMRI) improves the detection of significant prostate cancer (PC) and extraprostatic extension (EPE). We combined pre-biopsy mpMRI data and clinical parameters to develop a risk model (RM) to predict individual side-specific risk of EPE on radical prostatectomy (RP).
METHODS: MRI and clinical parameters of 132 men who underwent mpMRI fusion-biopsy and RP were analysed as training set. The RM was validated prospectively in 132 consecutive patients. Multivariate regression analysis was used to determine EPE predictors for RM development. The calibration of the RM was analysed using a calibration plot. The accuracy was compared to digital rectal examination (DRE), ESUR MRI criteria for EPE alone and the nomogram for side-specific EPE prediction of Steuber et al., using receiver operating characteristics (ROC) in training and validation set. Differences between the ROC curves were analysed using Likelihood ratio tests.
RESULTS: Primary Gleason pattern on biopsy on specific side, ESUR MRI criteria of side-specific lesion, PSA-density, clinical T-stage, lesion volume in milliliter and capsule contact length in millimeter on MRI were significant EPE-predictors and were included in the RM (Figure a) . The calibration plot of the RM showed that predicted and actual probabilities were close (slope 1.12) (Figure b) . ROC area under the curve (AUC) for the RM was significantly larger in both sets (0.88 and 0.84), compared to DRE (0.69, p¼0.004, 0.66, p<0.001 ) and the risk model of Steuber et al. (0.77, p¼0.009, 0.71, p¼0.006 ). Compared to ESUR criteria (AUC 0.87 and 0.80), the AUC was only significant larger in the validation set (p¼0.03) (Figure c/d) .
CONCLUSIONS: The RM, incorporating clinical and standardized MRI parameters performed significantly better compared to a renowned risk model, ESUR MRI criteria and clinical parameters alone. Thus, it provides accurate individual risk stratification of side-specific EPE of prostate cancers prior to RP. 
INTRODUCTION AND OBJECTIVES:
Identifying clinically significant prostate cancers is the main objective of prostate cancer diagnosis. The aim of this study was to develop, to internally validate and to calibrate a nomogram to predict the probability of detecting a clinically significant prostate cancer.
METHODS: Prospectively collected data from 3 tertiary referral center series of 478 consecutive patients who underwent MRI-US fusion biopsy using the UroStation (Koelis, France) were used to build the nomogram. A logistic regression model is created to identify predictors of PCa diagnosis with MRI-US fusion biopsy. Predictive accuracy was quantified using the concordance index (CI). Internal validation with 200 bootstrap resampling and calibration plot were performed.
RESULTS: Mean age was 66.3 yrs (AE 7.98) and mean PSA levels were 9.8 ng/mL (AE 7.98). The overall PCa detection rate was 57.4%. Age, PSA serum levels, PIRADS score at MRI report, number of targeted and number of systematic cores taken were included in the model (Figure 1 ). Predictive accuracy was 0.81. On internal validation the CI was 0.81 and predicted probability was well calibrated (Figure 2) .Limitations include the lack of external validation and the absence of patients with races different by Caucasian in the development cohort.
CONCLUSIONS: Predicting the risk of a clinically significant PCa is the goal of physicians. This nomogram provides a high accuracy in predicting the probability of diagnosing a clinically significant PCa with MRI-US fusion biopsy. The ease to use makes this nomogram a clinical tool for both patients and physicians. e22 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
